Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial

Author(s): Alexios Matikas, MD, PhD1,2; Volker Möbus, MD, PhD3; Richard Greil, MD, PhD4; Anne Andersson, MD, PhD5; Günther G. Steger, MD6; Michael Untch, MD, PhD7; Tommy Fornander, MD, PhD1; Per Malmström, MD, PhD8,9; Sabine Schmatloch, MD10; Mats Hellström, BSc2; Hemming Johansson, BSc1; Michael Gnant, MD, PhD11; Yvonne Brandberg, PhD1; Sibylle Loibl, MD, PhD12; Theodoros Foukakis, MD, PhD theodoros.foukakis@ki.se1,2; Jonas Bergh, MD, PhD1,2
Source: https://doi.org/10.1200/JCO.24.00178

Dr. Anjan Patel's Thoughts

Well done study showing a 20% decrease in recurrence risk when using dose dense therapy [EC]/D compared to conventional dose [FEC]/D. Sometimes it is worth it to push.

ABSTRACT

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Although dose-dense adjuvant chemotherapy administered once every 2 weeks leads to superior outcomes compared with standard regimens once every 3 weeks, the observed improvement is largely limited to studies using the suboptimal paclitaxel schedule once every 3 weeks as control. PANTHER is an international phase III trial which compared sequential epirubicin/cyclophosphamide and docetaxel administered either once every 2 or once every 3 weeks, with tailored dosing at the dose-dense schedule according to hematologic toxicity. In this end-of-study analysis, the median follow-up was 10.3 years. Compared with standard adjuvant chemotherapy, dose-dense treatment improved breast cancer recurrence-free survival (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.98]; P = .030), event-free survival (HR, 0.78 [95% CI, 0.65 to 0.94]; P = .009), and distant disease-free survival (HR, 0.79 [95% CI, 0.64 to 0.98]; P = .030) while the improvement in overall survival was not statistically significant (HR, 0.82 [95% CI, 0.65 to 1.04]; P = .109). To our knowledge, this is the first trial that confirms the benefit of a dose-dense regimen over a control regimen containing docetaxel once every 3 weeks.

Author Affiliations

1Oncology/Pathology Department, Karolinska Institutet, Stockholm, Sweden; 2Breast Center, Karolinska Comprehensive Cancer Center, Stockholm, Sweden; 3Department of Medicine II, Hematology & Oncology, University of Frankfurt, Frankfurt, Germany; 43rd Medical Department, Paracelsus Medical University and Salzburg Cancer Research Institute, Cancer Cluster Salzburg and AGMT, Salzburg, Austria; 5Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden; 6Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; 7Helios Klinikum Berlin-Buch, Berlin, Germany; 8Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; 9Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; 10Elisabeth Hospital, Kassel, Germany; 11Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 12German Breast Group, Neu-Isenburg, Germany

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial

The QUIWI study used quizartinib, a FLT3 drug added to standard chemo induction/consolidation in FLT-negative acute myeloid leukemia (AML) patients. There was a meaningful overall survival (OS) improvement across all age and risk groups including the NPM1+ population. They purposefully used a higher dose to achieve what is felt to be off-target TKI activity in familiar pathways of KIT, PDGRF…etc.

Read More »

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

This really feels like a first-line practice changer in PD-L1+ MTNBC—the sacituzumab govitecan/pembrolizumab combination delivering a 3.4-month progression-free survival (PFS) improvement and pushing median PFS past 11 months is quite meaningful. Mature overall survival (OS) data will be interesting to see. Remember to watch closely and consider screening for drug-induced interstitial lung disease(ILD).

Read More »

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

ASCENT-03 shows that in first-line, PD-1/PD-L1–ineligible advanced TNBC, sacituzumab improves PFS to 9.7 vs 6.9 months and extends median duration of response (DOR) to 12.2 vs 7.2 months, with similar overall response rate (ORR) (48% vs 46%) and immature overall survival (OS) (21.5 vs 20.2 months) Grade ≥3. Adverse events (AEs) were comparable (66% vs 62%), but sacituzumab had more neutropenia and diarrhea, fewer discontinuations (4% vs 12%), and early-cycle infection-related deaths in patients without primary G-CSF. For PD-1/PD-L1–ineligible mTNBC, SG offers more durable control than chemo with manageable myelosuppression — so consider SG first-line and start G-CSF early in higher-risk patients.

Read More »